The key part as some have already posted: "With Chk1 in good hands, Sareum is at liberty to focus on its other programmes towards the clinic. In 2017, we expect the completion of pre-clinical work on Aurora+FLT3, and progress on lead optimisation for TYK2, a novel programme in the JAK inhibitor family. On a risked basis, we still see the shares as significantly undervalued with the potential to double and on an un-risked basis see the potential to unlock value up to a share price of circa 4.5p, should its programmes progress up the development curve."
I'm from up this way, this tragic case has had lots of publicity on the local news, surely if the young lad is suitable they would have offered the trial? although I have no idea how thinks le this work.
Boss. Specifically because if you look at the compound factsheet they test it against "tofa" which is tofacacitinib aka xeljianz. Which is a pfizer marketed drug. Why ? None of the other compounds are compared to competitors. If you look at adisinsight it has also been un preclinical trials in the uk in autoimmune. But our autoimmune partners are based in sanfrancisco (sri). Sometimes 2+2 =5. Sometimes is doesnt.
Ruth plummer is in charge if the trials in newcastle which is closest. None of us are very intimate with the company unfortunately. Cruk and icr go on about lack of paediatric trials. And then they have the opportunity here and dont do it themselves.....
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.